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Recent studies have reported a significant increase of
proteinuria in kidney transplant recipients who were
switched from a calcineurin inhibitor (CI) to sirolimus. This
has (partly) been ascribed to the hemodynamic renal effects
of CI withdrawal. We have evaluated the evolution of
proteinuria in renal transplant recipients who underwent
conversion from azathioprine to sirolimus. In a randomized,
prospective, multicenter study called RESCUE (Recurrent
cutanEous Squamous cell Carcinoma Under RapamunE) the
efficacy and safety is investigated of conversion to sirolimus
in stable renal transplant recipients with a cutaneus
squamous cell carcinoma (SCC). In our center 25 patients
have been included in this study of which 13 patients were
randomized to continue their current immunosuppressive
treatment and 12 to conversion to sirolimus. After a mean
follow-up of 360 days mean proteinuria increased from
0.3770.34 to 1.8171.73 g/24 h after conversion to sirolimus
(Po0.005). In the control group there was no change in
proteinuria. A significant increase of proteinuria was
observed in all seven patients with proteinuria before
conversion, whereas proteinuria remained absent in all
patients without previous proteinuria. Two of the patients
with proteinuria were converted from cyclosporine and five
were converted from azathioprine to sirolimus. Sirolimus was
discontinued in five patients with proteinuria, and in all of
them proteinuria declined to baseline values. Our study
demonstrates that conversion from azathioprine to sirolimus
after kidney transplantation may cause a reversible increase
of proteinuria. Sirolimus-induced proteinuria therefore
cannot be ascribed to the hemodynamic renal effects of
withdrawal of CI.
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Squamous cell carcinoma (SCC) is the most common form
of malignancy after organ transplantation. The incidence of
SCC increases with the duration of immunosuppressive
therapy, ultimately affecting more than 50% of white
transplant recipients.1 Evidence suggests that sirolimus, an
effective immunosuppressive drug with antiproliferative
properties, may confer a decreased risk of malignancy. In a
randomized study the incidence of cancer, particularly skin
cancer, was lower in patients receiving sirolimus in
comparison with other immunosuppressive therapies.2 We
have initiated a randomized controlled study called RESCUE
(Recurrent cutanEous Squamous cell Carcinoma Under
RapamunE) to evaluate the efficacy of sirolimus in prevent-
ing new skin carcinomas in patients with at least one SCC in
an earlier phase after transplantation.
Sirolimus has also been reported to be less nephrotoxic
than other immunosuppressive agents used in transplanta-
tion. However, recent reports indicate that calcineurin
inhibitor (CI)-treated kidney transplant recipients may
develop a significant increase of proteinuria when switched
to sirolimus.3–10 The pathogenesis of this proteinuria is
unknown. In these studies most patients were switched from
CI to sirolimus because of progressive renal damage (chronic
allograft nephropathy with or without CI nephrotoxicity).
Therefore it was not possible to distinguish between the
hemodynamic renal effects of withdrawal of CI or a direct
toxic effect of sirolimus.
We have evaluated the evolution of proteinuria in patients
who participated in the above-mentioned randomized
controlled trial. Most of these patients were switched from
azathioprine to sirolimus, thus excluding any effects of CI
withdrawal.
RESULTS
In our center 25 patients have been included in the RESCUE
study until now. Thirteen patients were randomized to
continue their current immunosuppressive treatment and 12
were randomized to conversion to sirolimus.
One of the patients converted to sirolimus dropped out
because of the development of a hemolytic uremic syndrome.
After a mean follow-up of 360 days the mean proteinuria
level in the remaining 11 patients increased, whereas in the
control group there was no difference in proteinuria at
baseline and after a mean follow-up of 517 days (Table 1).
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An increase in proteinuria was observed in all patients
(n¼ 7) with proteinuria before conversion (from
0.5770.26 g/24 h to 2.8471.36 g/24 h; Po0.005)(Figure 1),
whereas proteinuria remained absent in all patients without
proteinuria (n¼ 4). Two of the patients with proteinuria were
converted from cyclosporine to sirolimus and five patients
were converted from azathioprine to sirolimus. There was no
difference in arterial blood pressure before and after the
switch to sirolimus and during sirolimus therapy no
angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker was added to the medication except in one
patient. In this patient 100 mg losartan was started after
which proteinuria did not increase further. The increase in
proteinuria started within 3 months after conversion in six of
the seven patients. Sirolimus was discontinued in five
patients with proteinuria, and in all of them proteinuria
declined to baseline values within 6 months.
In four of the seven patients who developed proteinuria
the excretion of low molecular weight proteins, a1-micro-
globulin and b2-microglobulin, in urine was determined. The
mean excretion of a1-microglobulin was 65 mg/10 mmol
creatinine (range 29–133) and of b2-microglobulin 6.1 mg/
10 mmol creatinine (range 0.2–20.4). These values are
elevated compared with normal values (o10 mg/10 mmol
creatinine and o0.3 mg/10 mmol creatinine, respectively).
The protein selectivity index, calculated as the clearance of
immunoglobulin G divided by the clearance of transferrin,
ranged from 0.16 to 0.31.
In the control group (n¼ 13) there was no difference in
serum creatinine at baseline and after a mean follow-up of
517 days (102720 and 103716 mmol/l, respectively). The
mean creatinine level in the sirolimus group (n¼ 11) slightly
increased from 109731 before to 118737 mmol/l after
conversion (P¼ 0.049)(Table 1). In the five patients who
were switched back to their old immunosuppressive regimen
because of proteinuria (n¼ 5) serum creatinine increased
after the introduction of sirolimus (from 118733 to
135737 mmol/l; Po0.01) and stabilized after reconversion
(131734 mmol/l; P¼ 0.19 compared with baseline).
DISCUSSION
Our results demonstrate that conversion from azathioprine
to sirolimus in stable renal transplant recipients with SCC
may cause a reversible increase of proteinuria. This increase
was seen only in patients with proteinuria at baseline.
Heavy glomerular proteinuria is an important and
independent predictor of progressive renal damage. Also in
the transplantation literature there is ample evidence that
persistent proteinuria is a strong risk factor for long-term
allograft loss and lower patient survival from cardiovascular
and all-cause mortality.11
Recent reports indicated that CI-treated kidney transplant
recipients might develop a significant increase of proteinuria
when switched to sirolimus.3–10 Diekmann et al.10 reported
that a proteinuria below 800 mg/day at conversion from CI to
sirolimus is the only independent predictor for positive
outcome in chronic allograft dysfunction. In these studies
most patients were switched from CI to sirolimus because of
progressive renal damage (chronic allograft nephropathy with
or without CI nephrotoxicity). The pathogenesis of this
proteinuria is unknown, but has (partly) been ascribed to the
hemodynamic renal effects of CI withdrawal. Morelon et al.3
suggested that CI withdrawal may lead to an increase in renal
blood flow responsible for the development of previously
masked proteinuria in patients with preexisting glomerular
damage.
Our data clearly indicate that this is not a satisfactory
explanation. Because in our study most of the patients who
developed proteinuria were switched from azathioprine to
sirolimus there must also be some direct nephrotoxic effect of
sirolimus. Whether sirolimus itself could affect glomerular
permeability is not known. In vitro studies have demons-
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Figure 1 | Evolution of proteinuria in the sirolimus-treated
patients. Individual data are given for seven patients with an
increased proteinuria after start of sirolimus. Sirolimus was withdrawn
in five patients, accompanied by reduction of proteinuria in all. Upper
reference value is indicated by the dotted line (0.2 g/24 h¼ normal).
Table 1 | Demographics
Sirolimus
(n=11)
Control
(n=13) P
Gender (male:female) 5:6 9:4 ns
Age (years) 55710 5778 ns
Previous immunosuppressive
therapy
Cyclosporine 3 1 ns
Azathioprine 8 11
MMF 0 1
Proteinuria (g/24 h)
At baseline 0.3770.34 0.3870.63 ns
At follow-up 1.8171.73** 0.2970.35 o0.05
Creatinine (mmol/l)
At baseline 109731 102720 ns
At follow-up 118737* 103716 ns
**Po0.005 versus baseline, *Po0.05 versus baseline.
Values are given as means7s.d.
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trated a tubulotoxic effect of sirolimus, especially in the
setting of prior renal injury.12 Straathof et al.13 described a
patient who developed heavy proteinuria during treatment
with sirolimus. They showed that a decrease in tubular
protein reabsorption contributed to the proteinuria. Experi-
mental studies of Coombes et al.14 have indicated that
sirolimus causes a specific pattern of acute renal injury
characterized by increased intratubular cast formation in
protein overload nephropathy. The increased excretion of low
molecular weight proteins a1-microglobulin and b2-micro-
globulin we found, might indicate that sirolimus promotes
proteinuria by blocking the tubular protein reabsorption.
Unfortunately we have no information about the urinary
excretion of small molecular weight proteins before conver-
sion to sirolimus. Admittedly, we cannot exclude that the
tubular proteinuria is the consequence of tubular injury
caused by glomerular protein leakage.
Sennesael et al.15 showed in renal transplant patients,
converted from CI to sirolimus, that proteinuria was
successfully treated with angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers. In only one of
our patients on sirolimus an angiotensin receptor blocker was
started after which proteinuria did not increase further.
Probably we could have kept more patients on sirolimus if we
started renin–angiotensin blockade.
In conclusion, switching renal transplant recipients from
azathioprine to sirolimus is associated with a reversible
increase in proteinuria. The mechanism of this effect remains
still unclear, but cannot be ascribed to the hemodynamic
renal effects of withdrawal of CI.
MATERIALS AND METHODS
In a randomized, prospective, multicenter study called RESCUE the
efficacy and safety is investigated of conversion to sirolimus in stable
renal transplant recipients with at least one cutaneous SCC. Patients
are randomized to continue their current immunosuppressive
regimen or are switched to sirolimus (trough levels of 5–10 ng/ml)
and prednisolone. We have evaluated the evolution of proteinuria in
patients in our hospital who were included in the RESCUE study.
According to current guidelines we have routinely used spot
urine samples and calculated protein–creatinine ratios for the
follow-up of our patients.16 All patients collected one or more 24 h
urine samples during the study period. As renal function was stable
proteinuria per 24 h can be calculated from the formula: proteinuria
(g/24 h)¼ proteincreatinine ratio (g/10 mmol creatinine) *creati-
nine excretion (mmol/24 h).
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